Trinity Historical Income Statement
| TRIB Stock | USD 1.12 0.01 0.88% |
Historical analysis of Trinity Biotech income statement accounts such as Cost Of Revenue of 43.5 M, Total Operating Expenses of 33 M, Interest Expense of 10.7 M or Selling General Administrative of 23.8 M can show how well Trinity Biotech plc performed in making a profits. Evaluating Trinity Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Trinity Biotech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Trinity Biotech plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Trinity Biotech plc is a good buy for the upcoming year.
Trinity |
About Trinity Income Statement Analysis
Trinity Biotech plc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Trinity Biotech shareholders. The income statement also shows Trinity investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Trinity Biotech Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Trinity Biotech plc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Trinity Biotech plc minus its cost of goods sold. It is profit before Trinity Biotech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Trinity Biotech plc. It is also known as Trinity Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Trinity Biotech plc income statement and represents the costs associated with goods and services Trinity Biotech provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Trinity Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Trinity Biotech plc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At present, Trinity Biotech's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 35.1 M, whereas Depreciation And Amortization is forecasted to decline to about 1.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 93.0M | 74.8M | 56.8M | 78.6M | Depreciation And Amortization | 2.7M | 2.3M | 1.8M | 1.7M |
Trinity Biotech income statement Correlations
Click cells to compare fundamentals
Trinity Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Trinity Biotech income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.9M | 3.1M | 2.7M | 2.3M | 1.8M | 1.7M | |
| Total Revenue | 90.4M | 102.0M | 93.0M | 74.8M | 56.8M | 78.6M | |
| Gross Profit | 38.1M | 48.6M | 38.1M | 22.0M | 19.5M | 35.1M | |
| Other Operating Expenses | 85.1M | 81.7M | 79.4M | 85.7M | 83.9M | 76.5M | |
| Operating Income | 872K | 19.1M | 13.2M | (10.9M) | (27.0M) | (25.7M) | |
| Ebit | 872K | 18.4M | 7.8M | (19.0M) | (25.9M) | (24.6M) | |
| Ebitda | 5.8M | 21.5M | 10.6M | (16.7M) | (24.1M) | (22.9M) | |
| Cost Of Revenue | 52.3M | 53.4M | 54.9M | 52.7M | 37.4M | 43.5M | |
| Total Operating Expenses | 32.8M | 28.3M | 24.5M | 33.0M | 46.5M | 33.0M | |
| Income Before Tax | 821K | (6.6M) | 751K | (41.2M) | (36.9M) | (35.1M) | |
| Total Other Income Expense Net | (51K) | (6.7M) | (5.9M) | (24.4M) | (9.9M) | (9.4M) | |
| Net Income | (4.1M) | (6.0M) | 875K | (41.0M) | (24.0M) | (22.8M) | |
| Income Tax Expense | 4.9M | (620K) | (178K) | (192K) | (59K) | (56.1K) | |
| Interest Expense | 4.9M | 5.5M | 5.5M | 24.7M | 10.1M | 10.7M | |
| Selling General Administrative | 27.6M | 25.1M | 24.7M | 29.2M | 31.2M | 23.8M | |
| Research Development | 5.3M | 5.1M | 4.5M | 4.1M | 4.4M | 4.9M | |
| Net Income Applicable To Common Shares | (22.1M) | (28.9M) | (6.4M) | 875K | 787.5K | 826.9K | |
| Discontinued Operations | 568K | 77K | (375K) | (54K) | (62.1K) | (65.2K) | |
| Net Income From Continuing Ops | (29.0M) | 15.7M | 9.2M | (41.0M) | (36.9M) | (35.0M) | |
| Tax Provision | (1.0M) | (182K) | (166K) | (192K) | (59K) | (62.0K) | |
| Interest Income | 2.1M | 697K | 36K | 3K | 303K | 0.0 | |
| Net Interest Income | (5.9M) | (4.9M) | (4.8M) | (24.4M) | (9.9M) | (10.4M) | |
| Reconciled Depreciation | 4.9M | 3.1M | 2.7M | 2.3M | 1.8M | 2.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.